Zacks.com on MSN13d
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
Atara stock plunges 41% upon the FDA issuance of a CRL against its BLA for Ebvallo to treat EBV+ PTLD. The company is also facing a severe cash crunch.
US FDA puts clinical hold on Atara's trials for cancer cell therapies
Atara Biotherapeutics said on Tuesday the U.S. health regulator has placed a clinical hold on its trials for cancer cell therapies, sending the drug developer's shares down more than 4% in premarket ...
Atara Biotherapeutics: Workforce Reductions and Regulatory Challenges Lead to Hold Rating
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on January 21.Invest with ...
American Association of Individual Investors15d
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Down 40.50%
Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 40.50%, which has investors questioning if this is right time to buy.
Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
Le Lézard9d
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLOtm (tabelecleucel) and ATA3219
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer ...
Reuters15d
US FDA declines to approve Atara Biotherapeutics' cancer therapy
Jan 16 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' (ATRA.O), opens new tab therapy to treat patients with a rare cancer that develops ...